Guillain-Barre Syndrome Treatment Market Size, Share and Global Trend By Type (Acute Inflammatory Demyelinating Polyradiculoneuropathy, Miller Fisher Syndrome, Acute Motor Axonal Neuropathy, Acute Motor-Sensory Axonal Neuropathy), By Treatment (Plasmapheresis, Immunoglobulin therapy, Others), By Route of Administration (Oral,Parental), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Regional Forecast, 2024-2032

Guillain-Barre Syndrome is a rare autoimmune disorder. In this case, the patients’ immune system attacks the nervous system. The causative agents of the Guillain-Barre Syndrome are still unknown. However, it is illuminated that the disease is often accompanied by infections including respiratory infection and stomach flu. The weakness in legs, difficulty in breathing, low or high blood pressure, restricted eye or facial movements are some of the common symptoms of the Guillain-Barre Syndrome.

According to the U.S. Library of Medicine, the prevalence of Guillain-Barre syndrome is estimated to be 6 to 40 cases per 1 million people. Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is the most common type Guillain-Barre Syndrome seen in North America and Europe, accounting for approximately 90 percent of cases of Guillain-Barré syndrome in those regions.

According to a study published by the PLOS One Journal in 2017, the Guillain-Barre syndrome is amongst some of the most common types of serious acute paralytic neuropathy. Moreover, an estimated 100,000 new cases of the disease were reported in 2017 globally. The increasing prevalence of Guillain-Barre syndrome is one of the major factors driving the growth of the global market in 2018.

However, lack of awareness for the disease, absence of any definitive treatment, and low per capita healthcare expenditures in the emerging countries are some of the factors restraining the Guillain-Barre syndrome treatment market growth during the projected period.

Key Players Covered

Some of the major companies that are present in the global Guillain- Barre syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and others.

SEGMENTATION

In 2018, among treatment, immunoglobulin therapy dominated the global Guillain-Barre syndrome due to its ease of administration and comparatively higher efficiency leading to rising demand from healthcare providers in emerging countries.This segment is projected to grow at comparatively higher CAGR during the forecast period.

Key Insights

• Epidemiology Guillain-Barre Syndrome (Key Countries/Regions)
• The Economic Cost Burden of Guillain- Barre Syndrome
• Pricing Analysis, By Treatment Type
• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis

North America dominated the global Guillain-Barre syndrome treatment market in 2018. Advanced and well-developed healthcare infrastructure and huge patient population in the region are some of the factors anticipated to drive the growth of the Guillain-Barre syndrome in North America. The increasing adoption of high-cost IVIG products and growing awareness among patient population leading to higher diagnosis rate in developed and emerging countries, are some of the factors driving the growth of the global Guillain-Barre syndrome treatment market. Additionally, a large number of market players in the U.S. market are focusing on R&D activities to introduce new therapeutic products for the treatment of Guillain–Barre syndrome. These factors are likely to fuel the growth of the Guillain-Barre syndrome treatment market in the North America. Asia Pacific is projected to grow at significant CAGR in the forecast period, due to the presence of a huge patient population and developing economies such as India and China within the region. Moreover, a large patient pool suffering due to infections by influenza and Zika virus, leading to triggering of the Guillain-Barre syndrome, is projected to fuel the demand for the diagnosis and treatment of the Guillain-Barre syndrome in the region.

Key Industry Developments

• In August 2018, Octapharma received approval from Health Canada for PANZYGA, an immunoglobulin developed for the treatment of patients with moderate to severe Guillain-Barre syndrome.
• in September 2017, CSL announced that the US FDA approved Privigen, an immunoglobulin developed for the treatment of adults with chronic Guillain-Barré syndrome.